NCT03474770View on ClinicalTrials.gov

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Focal Impaired Awareness Seizures
Interventions
DRUG

BIS-001ER

BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.

Trial Locations (2)

3050

The Alfred Hospital, Melbourne

The Royal Melbourne Hospital, Melbourne

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03474770 - BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Biotech Hunter | Biotech Hunter